Normalizing hematocrit in dialysis patients improves brain function

Pickett, Janiece L.; Theberge, David C.; Brown, Warren S.; Schweitzer, Suzanne; Nissenson, Allen R.

doi:10.1016/s0272-6386(99)70150-2

Cited by 221 publications

(120 citation statements)

References 17 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…A number of studies have recently demonstrated morbidity, mortality, and qualityof-life advantages to maintaining a hemoglobin level Ն11 g/dl in HD patients (37)(38)(39)(40)(41)(42)(43), and it is now widely appreciated that most patients require parenteral iron to achieve and maintain hemoglobin levels at or above this level (1,2). To our knowledge, no multicenter clinical trials are underway that have been designed a priori to compare the relative safety of different cumulative iron doses in HD patients.…”

Section: Discussionmentioning

confidence: 99%

Administration of Parenteral Iron and Mortality among Hemodialysis Patients

Feldman

Joffe²,

Robinson

et al. 2004

Journal of the American Society of Nephrology

174

140

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Administration of Parenteral Iron and Mortality among Hemodialysis Patients

Feldman

Joffe²,

Robinson

et al. 2004

Journal of the American Society of Nephrology

174

140

View full text Add to dashboard Cite

show abstract

“…Epoetin alfa has also been shown to cross the bloodbrain barrier and exhibit neuroprotective effects in preclinical studies (Brines et al, 2000;Cerami et al, 2001); and clinical trials in anaemic patients with chronic renal failure suggest that correction of anaemia with epoetin alfa improves brain and cognitive function (Marsh et al, 1991;Pickett et al, 1999).…”

mentioning

confidence: 99%

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy

Fallowfield

Gagnon

Zagari³

et al. 2002

Br J Cancer

112

View full text Add to dashboard Cite

Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because epoetin alfa has demonstrated efficacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving nonplatinum-based chemotherapy. The cancer-specific measures of quality of life included the general scale (FACT-G Total) and fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses of quality of life data were performed. Results of the univariate analysis have been reported previously. The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P50.05), and confirmed the results of the univariate analysis. For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (r, range: 0.14 -0.26, all P50.05) and between change in haemoglobin and change in quality of life (r, range: 0.26 -0.34, all P50.01). These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

show abstract

“…Some studies have suggested the possible relationship between the variability of the hemoglobin level and the patient [138,139] . Although there is variability in the results of different studies [120,131,[140][141][142][143] , the most consistent observation is that there are better results in terms of quality of life, with no increase in adverse reactions of hemoglobin in the range of 11-12 g/dL (hematocrit 33%) compared with lower levels [139][140][141][142][143][144] . There is a large study under way in relation to the normalization of hemoglobin.…”

Section: Hemoglobin Targetmentioning

confidence: 99%

“…Data from recent studies in CKD patients indicate increased morbidity and mortality in relation to high levels of hemoglobin (normal) [130][131][132][133] , as in patients with cancer [103,104] . It seems appropriate to establish a target hemoglobin level of 11-12 g/dL, which demonstrates greater benefit in quality of life and costeffectiveness in renal patients [120,133,[139][140][141][142][143][144][145] .…”

Section: Hemoglobin Targetmentioning

confidence: 99%

Use of agents stimulating erythropoiesis in digestive diseases

López¹,

Sicilia²,

García³

2009

WJG

View full text Add to dashboard Cite

Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as first choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same efficacy and safety.

show abstract

Normalizing hematocrit in dialysis patients improves brain function

Cited by 221 publications

References 17 publications

Administration of Parenteral Iron and Mortality among Hemodialysis Patients

Administration of Parenteral Iron and Mortality among Hemodialysis Patients

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy

Use of agents stimulating erythropoiesis in digestive diseases

Contact Info

Product

Resources

About